InnoCan Pharma Corporation (INNPF)

InnoCan Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb 10, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	25	42	63	40	157	49
Market Cap Growth	-32.14%	-33.43%	58.58%	-74.75%	220.33%	176.32%
Enterprise Value	22	39	59	33	151	47
Last Close Price	5.90	10.19	19.50	13.98	41.52	16.04
PS Ratio	0.93	1.42	4.61	15.50	801.47	6129.83
PB Ratio	3.79	5.96	14.34	6.37	17.43	-13.59
P/TBV Ratio	6.52	8.11	15.33	6.20	17.35	-
EV/Sales Ratio	0.80	1.32	4.32	12.89	771.51	5897.57
Debt / Equity Ratio	0.23	0.00	0.01	0.01	0	-0.01
Net Debt / Equity Ratio	-0.87	-0.71	-0.88	-0.79	-1.23	0.92
Net Debt / EBITDA Ratio	4.73	4.12	1.02	0.79	1.49	0.71
Net Debt / FCF Ratio	-10.30	3.14	0.98	0.81	1.66	0.90
Asset Turnover	2.61	3.63	1.96	0.26	0.02	0.00
Inventory Turnover	1.06	1.28	1.17	0.55	0.16	-
Quick Ratio	2.72	2.48	1.79	7.10	3.15	0.44
Current Ratio	3.72	4.09	2.68	9.41	3.51	0.54
Return on Equity (ROE)	-33.07%	-4.59%	-80.07%	-51.05%	-373.46%	-
Return on Assets (ROA)	-7.56%	-9.62%	-34.16%	-40.06%	-55.30%	-85.40%
Return on Invested Capital (ROIC)	-145.92%	27.80%	-412.03%	-	-	-
Return on Capital Employed (ROCE)	-15.40%	-17.80%	-86.50%	-100.30%	-83.00%	131.00%
Earnings Yield	-12.86%	-4.38%	-7.47%	-9.49%	-6.40%	-20.30%
FCF Yield	2.22%	-3.81%	-6.28%	-15.36%	-4.25%	-7.52%
Buyback Yield / Dilution	-5.42%	-8.96%	-3.23%	-10.87%	-38.59%	-34.30%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.